FI114286B - Menetelmä mykofenolaattimofetiilia, mykofenolihappoa tai ranolatsiinia sisältävien farmaseuttisten valmisteiden valmistamiseksi - Google Patents
Menetelmä mykofenolaattimofetiilia, mykofenolihappoa tai ranolatsiinia sisältävien farmaseuttisten valmisteiden valmistamiseksi Download PDFInfo
- Publication number
- FI114286B FI114286B FI955439A FI955439A FI114286B FI 114286 B FI114286 B FI 114286B FI 955439 A FI955439 A FI 955439A FI 955439 A FI955439 A FI 955439A FI 114286 B FI114286 B FI 114286B
- Authority
- FI
- Finland
- Prior art keywords
- mycophenolate mofetil
- temperature
- capsule
- active substance
- condensed
- Prior art date
Links
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 title claims abstract description 59
- 229960004866 mycophenolate mofetil Drugs 0.000 title claims abstract description 58
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 title claims abstract description 33
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 title claims abstract description 22
- 229960000951 mycophenolic acid Drugs 0.000 title claims abstract description 14
- 238000000034 method Methods 0.000 title claims description 32
- 238000002360 preparation method Methods 0.000 title claims description 18
- XKLMZUWKNUAPSZ-UHFFFAOYSA-N N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide Chemical compound COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC=2C(=CC=CC=2C)C)CC1 XKLMZUWKNUAPSZ-UHFFFAOYSA-N 0.000 title claims description 13
- 229960000213 ranolazine Drugs 0.000 title claims description 12
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 7
- 239000007788 liquid Substances 0.000 claims abstract description 25
- 239000002552 dosage form Substances 0.000 claims abstract description 14
- 239000002775 capsule Substances 0.000 claims description 41
- 238000002844 melting Methods 0.000 claims description 24
- 230000008018 melting Effects 0.000 claims description 24
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 20
- 239000013543 active substance Substances 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 11
- 238000010438 heat treatment Methods 0.000 claims description 10
- 239000000945 filler Substances 0.000 claims description 5
- 238000002425 crystallisation Methods 0.000 claims description 2
- 230000008025 crystallization Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000002270 dispersing agent Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 abstract description 25
- 238000009472 formulation Methods 0.000 abstract description 21
- 238000011049 filling Methods 0.000 abstract description 18
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 239000012943 hotmelt Substances 0.000 abstract description 4
- 239000008203 oral pharmaceutical composition Substances 0.000 abstract description 2
- 239000007903 gelatin capsule Substances 0.000 description 19
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 17
- 239000004480 active ingredient Substances 0.000 description 16
- 229920002785 Croscarmellose sodium Polymers 0.000 description 15
- 229960001681 croscarmellose sodium Drugs 0.000 description 15
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 11
- 238000001816 cooling Methods 0.000 description 10
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 229920002678 cellulose Polymers 0.000 description 6
- 239000001913 cellulose Substances 0.000 description 6
- 235000010980 cellulose Nutrition 0.000 description 6
- 239000007884 disintegrant Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 239000001828 Gelatine Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- -1 mycopheno- Chemical class 0.000 description 4
- 229940014456 mycophenolate Drugs 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- WNWVKZTYMQWFHE-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound [CH2]CN1CCOCC1 WNWVKZTYMQWFHE-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 3
- 239000007902 hard capsule Substances 0.000 description 3
- 229960001680 ibuprofen Drugs 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 229950007856 mofetil Drugs 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- QQONPFPTGQHPMA-UHFFFAOYSA-N Propene Chemical compound CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000012768 molten material Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000007711 solidification Methods 0.000 description 2
- 230000008023 solidification Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000009974 thixotropic effect Effects 0.000 description 2
- GNXFOGHNGIVQEH-UHFFFAOYSA-N 2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate Chemical compound COC1=CC=CC=C1OCC(O)COC(N)=O GNXFOGHNGIVQEH-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- HZAAQSZZIYJZKF-UHFFFAOYSA-N 4-methylhex-4-enoic acid Chemical compound CC=C(C)CCC(O)=O HZAAQSZZIYJZKF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 210000003323 beak Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000011449 brick Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960003627 gemfibrozil Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229960002146 guaifenesin Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940127021 low-dose drug Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229960002330 methocarbamol Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012057 packaged powder Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-M phenolate Chemical compound [O-]C1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-M 0.000 description 1
- 229940031826 phenolate Drugs 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000004781 supercooling Methods 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Transplantation (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/061,656 US5455045A (en) | 1993-05-13 | 1993-05-13 | High dose formulations |
| US6165693 | 1993-05-13 | ||
| PCT/US1994/005196 WO1994026266A1 (en) | 1993-05-13 | 1994-05-10 | High dose formulations |
| US9405196 | 1994-05-10 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI955439A0 FI955439A0 (fi) | 1995-11-10 |
| FI955439L FI955439L (fi) | 1995-11-10 |
| FI114286B true FI114286B (fi) | 2004-09-30 |
Family
ID=22037233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI955439A FI114286B (fi) | 1993-05-13 | 1995-11-10 | Menetelmä mykofenolaattimofetiilia, mykofenolihappoa tai ranolatsiinia sisältävien farmaseuttisten valmisteiden valmistamiseksi |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US5455045A (cs) |
| EP (1) | EP0697866B1 (cs) |
| JP (1) | JP3584037B2 (cs) |
| KR (1) | KR100296214B1 (cs) |
| CN (1) | CN1045884C (cs) |
| AT (1) | ATE187067T1 (cs) |
| AU (1) | AU674960B2 (cs) |
| BR (2) | BR9406604A (cs) |
| CZ (1) | CZ285297B6 (cs) |
| DE (1) | DE69421918T2 (cs) |
| DK (1) | DK0697866T3 (cs) |
| ES (1) | ES2138661T3 (cs) |
| FI (1) | FI114286B (cs) |
| GR (1) | GR3032021T3 (cs) |
| HU (2) | HU226470B1 (cs) |
| IL (1) | IL109639A (cs) |
| NO (1) | NO308828B1 (cs) |
| NZ (1) | NZ266683A (cs) |
| PL (1) | PL175583B1 (cs) |
| PT (1) | PT697866E (cs) |
| RU (1) | RU2135182C1 (cs) |
| TW (1) | TW434010B (cs) |
| WO (1) | WO1994026266A1 (cs) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69013923T2 (de) * | 1989-08-17 | 1995-03-16 | Cortecs Ltd., Isleworth | Arzneiformulierungen. |
| US5455045A (en) * | 1993-05-13 | 1995-10-03 | Syntex (U.S.A.) Inc. | High dose formulations |
| MX9707585A (es) * | 1995-04-03 | 1997-12-31 | Abbott Lab | Mezclas homogeneas de farmacos y aditivos de fusion a baja temperatura para liberacion controlada. |
| ID18663A (id) * | 1996-04-12 | 1998-04-30 | Novartis Ag | Komposisi farmasi berlapis enterik |
| UA72207C2 (uk) * | 1998-04-07 | 2005-02-15 | Брістол- Майєрс Сквібб Фарма Компані | Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення |
| US6479496B1 (en) * | 1998-09-10 | 2002-11-12 | Cv Therapeutics, Inc. | Methods for treating angina with ranolazine |
| US6303607B1 (en) * | 1998-09-10 | 2001-10-16 | Cv Therapeutics, Inc. | Method for administering a sustained release ranolanolazine formulation |
| BR0108452A (pt) | 2000-02-18 | 2003-04-01 | Cv Therapeutics Inc | Inibidores da oxidação parcial de ácido graxo no tratamento de insuficiência cardìaca congestiva |
| AU2001239827A1 (en) | 2000-02-22 | 2001-09-03 | Cv Therapeutics, Inc. | Substituted alkylene diamine compounds |
| WO2001062749A1 (en) | 2000-02-22 | 2001-08-30 | Cv Therapeutics, Inc. | Substituted piperazine compounds |
| US6552023B2 (en) | 2000-02-22 | 2003-04-22 | Cv Therapeutics, Inc. | Aralkyl substituted piperazine compounds |
| US6451798B2 (en) | 2000-02-22 | 2002-09-17 | Cv Therapeutics, Inc. | Substituted alkyl piperazine derivatives |
| US6677336B2 (en) | 2000-02-22 | 2004-01-13 | Cv Therapeutics, Inc. | Substituted piperazine compounds |
| US6573264B1 (en) * | 2000-10-23 | 2003-06-03 | Cv Therapeutics, Inc. | Heteroaryl alkyl piperazine derivatives |
| GB0124953D0 (en) * | 2001-10-17 | 2001-12-05 | Novartis Ag | Organic Compounds |
| US8822473B2 (en) * | 2002-05-21 | 2014-09-02 | Gilead Sciences, Inc. | Method of treating diabetes |
| IL165304A0 (en) * | 2002-05-21 | 2006-01-15 | Cv Therapeutics Inc | Method of treating diabetes |
| ES2327873T3 (es) * | 2002-12-05 | 2009-11-04 | Cv Therapeutics, Inc. | Compuestos de piperazina sustituidos y su utilizacion como inhibidores de la oxidacion de acidos grasos. |
| US7205303B2 (en) * | 2003-01-03 | 2007-04-17 | Cv Therapeutics, Inc. | Substituted heterocyclic compounds |
| AU2004209522A1 (en) * | 2003-01-17 | 2004-08-19 | Gilead Palo Alto, Inc. | Substituted heterocyclic compounds useful in the treatment of cardiovascular diseases |
| GB0307553D0 (en) * | 2003-04-01 | 2003-05-07 | Novartis Ag | Organic compounds |
| US20050187170A1 (en) * | 2003-06-16 | 2005-08-25 | Biocryst Pharmaceuticals, Inc. | Enhancing the efficiency of RNA polymerase inhibitors by using inosine monophosphate dehydrogenase inhibitors |
| WO2005000826A1 (en) * | 2003-06-23 | 2005-01-06 | Cv Therapeutics, Inc. | Urea derivatives of piperazines and piperidines as fatty acid oxidation inhibitors |
| AU2004303882A1 (en) | 2003-12-18 | 2005-07-07 | Gilead Palo Alto, Inc. | 1-akan-2-ol substituted piperazine and piperidine compounds |
| TW200613294A (en) * | 2004-04-26 | 2006-05-01 | Teva Gyogyszergyar Reszvenytarsasag | Process for preparation of mycophenolic acid and ester derivatives thereof |
| CA2555461A1 (en) * | 2004-04-27 | 2005-11-10 | Teva Gyogyszergyar Zartkoeruen Mukoedo Reszvenytarsasag | Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid |
| US20110104186A1 (en) | 2004-06-24 | 2011-05-05 | Nicholas Valiante | Small molecule immunopotentiators and assays for their detection |
| CA2573784A1 (en) * | 2004-07-20 | 2006-02-02 | Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag | Crystalline mycophenolate sodium |
| CA2579621A1 (en) * | 2004-09-08 | 2006-03-16 | Cv Therapeutics, Inc. | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors |
| KR20070093988A (ko) * | 2005-01-06 | 2007-09-19 | 씨브이 쎄러퓨틱스, 인코포레이티드 | 라놀라진 함유 서방성 약제학적 제형물 |
| CN100393312C (zh) * | 2005-04-18 | 2008-06-11 | 吴建梅 | 霉酚酸或其类似物的软胶囊及其制备方法 |
| US20080281111A1 (en) * | 2005-04-26 | 2008-11-13 | Sandor Molnar | Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid |
| WO2008003769A2 (en) * | 2006-07-06 | 2008-01-10 | Ares Trading S.A. | An oral pharmaceutical composition of an anilinopyrimidine, its preparation and use thereof |
| EP2051583A4 (en) * | 2006-08-16 | 2011-09-14 | Aspreva Pharmaceuticals Ltd | COMPOSITIONS AND METHODS FOR TREATING VASCULAR, AUTOIMMUNE AND INFLAMMATORY DISEASES |
| EP2117550A1 (en) * | 2007-02-13 | 2009-11-18 | CV Therapeutics Inc. | Use of ranolazine for the treatment of non-coronary microvascular diseases |
| WO2008101008A1 (en) * | 2007-02-13 | 2008-08-21 | Cv Therapeutics, Inc. | Use of ranolazine for the treatment of coronary microvascular diseases |
| US20090111826A1 (en) * | 2007-02-13 | 2009-04-30 | Louis Lange | Use of ranolazine for the treatment of cardiovascular diseases |
| EP2117509A1 (en) | 2007-02-13 | 2009-11-18 | CV Therapeutics Inc. | Use of ranolazine for the treatment of cardiovascular diseases |
| US20080233191A1 (en) * | 2007-03-22 | 2008-09-25 | Brent Blackburn | Use of ranolazine for elevated brain-type natriuretic peptide |
| ES2402675T3 (es) * | 2007-05-31 | 2013-05-07 | Gilead Palo Alto, Inc. | Ranolazina para el péptido natriurético de tipo cerebral a niveles elevados |
| US20090076000A1 (en) * | 2007-09-15 | 2009-03-19 | Protia, Llc | Deuterium-enriched mycophenolate mofetil |
| AR068745A1 (es) * | 2007-10-08 | 2009-12-02 | Panacea Biotec Ltd | Una composicion en forma de dosificacion farmaceutica oral de unidad de alta dosis de micofenolato sodico, metodo para utilizar dicha composicion y sus usos |
| BRPI0908428A2 (pt) * | 2008-02-06 | 2015-12-08 | Gilead Sciences Inc | uso de ranozalina para tratar a dor. |
| JP2011527339A (ja) * | 2008-07-09 | 2011-10-27 | アスプレバ インターナショナル リミテッド | 眼障害を処置するためのミコフェノール酸ナトリウムのｐＨ特異的な溶液 |
| EP2326717A4 (en) | 2008-08-26 | 2011-12-28 | Intelligentnano Inc | ON THE BASIS OF ULTRASONIC REINFORCED GROWTH OF MICROORGANISMS |
| US8962290B2 (en) | 2008-08-26 | 2015-02-24 | Intelligentnano Inc. | Enhanced animal cell growth using ultrasound |
| US9012192B2 (en) * | 2008-08-26 | 2015-04-21 | Intelligentnano Inc. | Ultrasound enhanced growth of microorganisms |
| MX2011012140A (es) * | 2009-05-14 | 2012-02-28 | Gilead Sciences Inc | Ranolazina para el tratamiento de problemas del snc. |
| CN105640918A (zh) * | 2009-05-19 | 2016-06-08 | 细胞基因公司 | 4-氨基-2-(2,6-二氧代哌啶-3-基)异吲哚啉-1,3-二酮的制剂 |
| WO2010137040A2 (en) | 2009-05-28 | 2010-12-02 | Lupin Limited | Novel pharmaceutical compositions of ranolazine |
| EP2480234B1 (en) | 2009-09-25 | 2020-02-26 | Lupin Limited | Sustained release composition of ranolazine |
| TWI508726B (zh) | 2009-12-21 | 2015-11-21 | Gilead Sciences Inc | 治療心房纖維性顫動之方法 |
| TW201215392A (en) | 2010-06-16 | 2012-04-16 | Gilead Sciences Inc | Use of ranolazine for treating pulmonary hypertension |
| KR20230079115A (ko) | 2020-09-27 | 2023-06-05 | 차이나 페트로리움 앤드 케미컬 코포레이션 | 불균등화 및 트랜스알킬화 촉매, 이의 제조 및 응용 |
| CN114456835B (zh) | 2020-10-22 | 2023-06-06 | 中国石油化工股份有限公司 | 一种汽油组分的处理系统和处理方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3374146A (en) * | 1966-04-18 | 1968-03-19 | American Cyanamid Co | Sustained release encapsulation |
| US3705946A (en) * | 1971-05-25 | 1972-12-12 | Lilly Co Eli | Method of treating hyperuricemia |
| JPS5542995B2 (cs) * | 1972-02-24 | 1980-11-04 | ||
| US3880995A (en) * | 1973-05-14 | 1975-04-29 | Lilly Co Eli | Treatment of arthritis with mycophenolic acid and derivatives |
| US3903071A (en) * | 1973-05-22 | 1975-09-02 | Lilly Co Eli | Mycophenolic acid derivatives |
| US4002718A (en) * | 1974-10-16 | 1977-01-11 | Arnar-Stone Laboratories, Inc. | Gelatin-encapsulated digoxin solutions and method of preparing the same |
| US4145918A (en) * | 1976-09-07 | 1979-03-27 | Akzona Incorporated | Freeze-thaw indicator |
| GB1572226A (en) * | 1977-11-03 | 1980-07-30 | Hoechst Uk Ltd | Pharmaceutical preparations in solid unit dosage form |
| DE2908794C2 (de) * | 1978-03-09 | 1984-09-13 | Japan Atomic Energy Research Institute, Tokio/Tokyo | Verfahren zur Herstellung eines eine physiologisch aktive Substanz enthaltenden Polymerpräparates |
| US4567264A (en) * | 1983-05-18 | 1986-01-28 | Syntex (U.S.A.) Inc. | Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry |
| DK164642C (da) * | 1984-08-30 | 1992-12-14 | Merrell Dow Pharma | Farmaceutisk middel indeholdende terfenadin i form af en varmsmelte paafyldt paa kapsler |
| DE3438830A1 (de) * | 1984-10-23 | 1986-04-30 | Rentschler Arzneimittel | Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung |
| US4820523A (en) * | 1986-04-15 | 1989-04-11 | Warner-Lambert Company | Pharmaceutical composition |
| DE3613799C1 (de) * | 1986-04-24 | 1987-09-03 | Nattermann A & Cie | Verwendung von Glycofurol zum Verfluessigen von Arzneimittelzubereitungen fuer das Abfuellen in Weichgelatinekapseln |
| US4727069A (en) * | 1987-01-30 | 1988-02-23 | Syntex (U.S.A.) Inc. | Heterocyclic aminoalkyl esters of mycophenolic acid, derivatives thereof and pharmaceutical compositions |
| US4753935A (en) * | 1987-01-30 | 1988-06-28 | Syntex (U.S.A.) Inc. | Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions |
| US5175000A (en) * | 1987-06-30 | 1992-12-29 | Vipont Pharmaceutical, Inc. | Free amine benzophenanthridine alkaloid compositions |
| US4936074A (en) * | 1988-11-17 | 1990-06-26 | D. M. Graham Laboratories, Inc. | Process for preparing solid encapsulated medicament |
| AU5419690A (en) * | 1989-03-31 | 1990-11-05 | Children's Medical Center Corporation | Treatment of aids dementia, myelopathy and blindness |
| ATE119766T1 (de) * | 1989-10-26 | 1995-04-15 | Nippon Shinyaku Co Ltd | Zubereitung für den magen. |
| FR2657257B1 (fr) * | 1990-01-19 | 1994-09-02 | Rhone Poulenc Sante | Procede de preparation de medicaments sous forme de perles. |
| KR100215167B1 (ko) * | 1990-08-10 | 1999-08-16 | 위샤르트 아이 시 | 면역 억제 조성물 |
| US5247083A (en) * | 1992-07-10 | 1993-09-21 | Syntex (U.S.A.) Inc. | Direct esterification of mycophenolic acid |
| US5455045A (en) * | 1993-05-13 | 1995-10-03 | Syntex (U.S.A.) Inc. | High dose formulations |
| US5380879A (en) * | 1994-02-18 | 1995-01-10 | Syntex (U.S.A.) Inc. | Derivatives of mycophenolic acid |
| US5467037A (en) * | 1994-11-21 | 1995-11-14 | International Business Machines Corporation | Reset generation circuit to reset self resetting CMOS circuits |
-
1993
- 1993-05-13 US US08/061,656 patent/US5455045A/en not_active Expired - Lifetime
-
1994
- 1994-04-25 TW TW083103771A patent/TW434010B/zh not_active IP Right Cessation
- 1994-05-09 US US08/239,621 patent/US5472707A/en not_active Expired - Lifetime
- 1994-05-10 AT AT94916722T patent/ATE187067T1/de active
- 1994-05-10 KR KR1019950704984A patent/KR100296214B1/ko not_active Expired - Lifetime
- 1994-05-10 RU RU95122420A patent/RU2135182C1/ru active
- 1994-05-10 CN CN94192045A patent/CN1045884C/zh not_active Expired - Lifetime
- 1994-05-10 CZ CZ952954A patent/CZ285297B6/cs not_active IP Right Cessation
- 1994-05-10 PL PL94311654A patent/PL175583B1/pl unknown
- 1994-05-10 HU HU9503224A patent/HU226470B1/hu unknown
- 1994-05-10 DK DK94916722T patent/DK0697866T3/da active
- 1994-05-10 WO PCT/US1994/005196 patent/WO1994026266A1/en active IP Right Grant
- 1994-05-10 BR BR9406604A patent/BR9406604A/pt not_active Application Discontinuation
- 1994-05-10 ES ES94916722T patent/ES2138661T3/es not_active Expired - Lifetime
- 1994-05-10 AU AU68301/94A patent/AU674960B2/en not_active Expired
- 1994-05-10 JP JP52565394A patent/JP3584037B2/ja not_active Expired - Lifetime
- 1994-05-10 PT PT94916722T patent/PT697866E/pt unknown
- 1994-05-10 EP EP94916722A patent/EP0697866B1/en not_active Expired - Lifetime
- 1994-05-10 NZ NZ266683A patent/NZ266683A/en not_active IP Right Cessation
- 1994-05-10 DE DE69421918T patent/DE69421918T2/de not_active Expired - Lifetime
- 1994-05-12 IL IL109639A patent/IL109639A/en not_active IP Right Cessation
-
1995
- 1995-04-24 HU HU95P/P00110P patent/HU211270A9/hu unknown
- 1995-06-02 US US08/459,227 patent/US5554384A/en not_active Expired - Lifetime
- 1995-11-10 NO NO954546A patent/NO308828B1/no not_active IP Right Cessation
- 1995-11-10 FI FI955439A patent/FI114286B/fi not_active IP Right Cessation
-
1997
- 1997-05-09 BR BR1100723-0A patent/BR1100723A/pt active IP Right Grant
-
1999
- 1999-12-02 GR GR990401633T patent/GR3032021T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI114286B (fi) | Menetelmä mykofenolaattimofetiilia, mykofenolihappoa tai ranolatsiinia sisältävien farmaseuttisten valmisteiden valmistamiseksi | |
| BG64411B1 (bg) | Фармацевтичен състав | |
| IL263161A (en) | New compounds for the treatment of parasitic diseases | |
| CA2870240A1 (en) | Analgesic | |
| HU195421B (en) | Process for producing melted antihistamine compositions | |
| GB2614741A (en) | A liquid pharmaceutical formulation of clonidine hydrochloride | |
| WO2021163023A1 (en) | Stable formulations of dronabinol | |
| IE75203B1 (en) | 5-HT1-like receptor agonist for rectal administration | |
| DK156121B (da) | Fremgangsmaade til fremstilling af et rectalt administrerbart suppositorium indeholdende et adjuvans | |
| KR20020064289A (ko) | 약제학적 담체 제형 | |
| JP4711961B2 (ja) | ２−メトキシメチル−３−（３，４−ジクロロフェニル）−８−アザビシクロ［３．２．１］オクタン酒石酸塩 | |
| CN114349745B (zh) | 一种用于治疗心肌缺血的药物及其制备方法 | |
| CA2162670C (en) | High dose formulations of mycophenolate mofetil, mycophenolic acid and ranolazine | |
| KR20010021796A (ko) | 선택성 세로토닌 재흡수 억제제 (ｓｓｒｉ)를 사용하는심장 질환의 치료 및 예방법 | |
| JPS6150915A (ja) | 抗アンギナ医薬組成物 | |
| CA3217719A1 (en) | Phenoxyalkylcarboxylic acid derivatives and their use in lowering triglyceride levels | |
| TW201536282A (zh) | 治療抑鬱症之迪米拉西坦（ｄｉｍｉｒａｃｅｔａｍ） | |
| CZ200085A3 (cs) | Léčivo proti srdečním poruchám a farmaceutický prostředek s obsahem SSRI | |
| BG104939A (bg) | Лечение на общо чувство на безпокойство с пароксетин | |
| GB2219938A (en) | Use of a thromboxane receptor antagonist in pregnancy-induced hypertension | |
| CN105859869A (zh) | 粒细胞巨噬细胞刺激因子及其制剂和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Patent granted |
Ref document number: 114286 Country of ref document: FI |
|
| MA | Patent expired |